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Abstract: p21Waf/CIP1 is a small unstructured protein that binds and inactivates cyclin-dependent
kinases (CDKs). To this end, p21 levels increase following the activation of the p53 tumor suppressor.
CDK inhibition by p21 triggers cell-cycle arrest in the G1 and G2 phases of the cell cycle. In the
absence of exogenous insults causing replication stress, only residual p21 levels are prevalent that are
insufficient to inhibit CDKs. However, research from different laboratories has demonstrated that
these residual p21 levels in the S phase control DNA replication speed and origin firing to preserve
genomic stability. Such an S-phase function of p21 depends fully on its ability to displace partners
from chromatin-bound proliferating cell nuclear antigen (PCNA). Vice versa, PCNA also regulates
p21 by preventing its upregulation in the S phase, even in the context of robust p21 induction by γ
irradiation. Such a tight regulation of p21 in the S phase unveils the potential that CDK-independent
functions of p21 may have for the improvement of cancer treatments.
Keywords: p21CDKN1A; CDK; PCNA; TLS; S phase; DNA replication
1. A Broadly Accepted Notion: p21 Controls the Cell Cycle through Cyclin Kinases Inhibition
Before starting to discuss nuclear functions of cyclin kinase inhibitor p21 (also known as
p21Waf/CIP1/CDKN1A) we mention that, even though the cytoplasmic functions of p21 were
described [1–3], these are not the focus of this review. p21 is a 165 amino acid protein characterized
by high intrinsic molecular flexibility and nondefined tertiary structure unless when bound to other
proteins [4]. At its N-terminus, p21 binds cyclins D/E/A and B, and cyclin-dependent kinases CDK4/6,
CDK2, and CDK1 [5–7]. In order to achieve CDK inhibition, p21 must simultaneously bind to both
cyclin and CDKs [8–10]. In cells, serum starvation causes p21 accumulation to such an extent that it
titrates and inactivates CDK/cyclin complexes, and allows the accumulation of free p21 in G1 [11].
Endogenous p21 upregulation can also be achieved after the treatment of cells with DNA-damaging
agents such as γ irradiation, which causes DNA double-strand breaks (DSBs) and other types of
DNA lesions, such as DNA–protein cross-links, oxidized bases, and abasic sites. DNA lesions block
replication forks, causing the formation of replication intermediates that activate the DNA damage
response (DDR). Kinases within the DDR network phosphorylate p53 and its E3 ubiquitin ligase mouse
double minute 2 (Mdm-2), impairing their interaction [12]. As a consequence, p53 levels accumulate,
and its transcriptional targets are augmented. Because of the two strong p53-responsive elements
within the p21 promoter, p21 mRNA levels increase steeply and rapidly upon p53 upregulation [13].
High p21 levels trigger arrest in Phases G1 and G2 of the cell cycle [5,14,15]. In fact, live tracking of
single cells expressing p21-green fluorescent protein (GFP) revealed that G1 cells express the highest
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and most variable p21-GFP levels that correlate strongly with the length of the G1 phase. The levels of
p21-GFP in Phase G2 are lower and less variable than in Phase G1, and they correlate to a lesser extent
with G2 phase length [16]. By monitoring CDK2 activity in living cells, previous work also showed
that p21 levels at the end of mitosis control cell fate, either by allowing CDK2 activity to build up the
next cell cycle, or by inhibiting CDK2 and getting the cell into a G0 state [17]. It is, therefore, expected
that p21 expression causes a reduction in the number of cells transiting the S phase. Such a change in
cell-cycle distribution generates a time window to repair damaged DNA [12]. p21 is also essential for
the prevention of endoreduplication and induction of senescence after extended cell-cycle arrest [18,19].
Because of such a central role in cell-cycle control, p21 is accepted as a bona fide tumor suppressor.
Such a notion spread widely in the scientific community and is even found in biology student textbooks.
While the validity of such conclusions is not in question, this review focuses on evidence indicating that
the nuclear functions of p21 are not at all restricted to the inhibition of CDKs. In fact, we extensively
discuss functions of p21 in the S phase that are insufficient to inhibit CDKs.
2. Can Cell-Cycle Arrest Be Achieved by p21–PCNA Interaction?
With its C terminus, p21 interacts with the proliferating cell nuclear antigen (PCNA), a protein
that was discovered in 1978 and was initially described as an essential factor for proliferation [20].
Many years later, in 1996, the first crystal structure of human PCNA was reported, and it happened to
be crystalized with a 22 amino acid peptide corresponding to the C terminus of p21 [21]. PCNA is
a torus-shaped homotrimeric ring that encircles DNA and slides in the direction of the replication
fork. It provides an anchor point for DNA polymerases in the proximity to DNA, favoring their
processivity. While PCNA was initially identified as a processivity factor for DNA polymerases [22],
it is now clear that it interacts with hundreds of proteins with known functions in cell-cycle regulation,
DNA replication, and DNA repair processes [23–26]. The majority of such interactions happen through
a conserved motif on the surface of PCNA, the 16 amino acid long interdomain connecting loop (IDCL),
which interacts with the PCNA-interacting protein (PIP) box of protein partners [25].
PIP boxes reside in intrinsically disordered regions of proteins. The PIP box consensus sequence
was defined as Qxxφxxψψ, where, by definition, Q is glutamine, x is any amino acid,φ is a hydrophobic
residue, and ψ an aromatic residue (commonly Phe or Tyr) [27]. The p21 peptide used in the original
PCNA crystal structure (139GRKRRQTSMTDFYHSKRRLIFS160) [21] contains p21 PIP box QTSMTDFY
(aa 144 to 151) that fulfills all consensus sequence requirements. The PIP box of p21 is actually a PIP
degron that targets PCNA-interacting proteins for proteasomal degradation via E3 ubiquitin ligase
CRL4Cdt2. PIP degrons are formed by a threonine and an aspartic acid (TD) within the PIP box,
and a basic residue (R) in the +4 position from the last residue of the PIP box [28]. A very recent report
demonstrated that the outstanding affinity of p21 for PCNA depends not only on such a core, but also
on sequences that flank such a region (aa 140 to 143 and aa 152 to 164). Without those sequences,
the affinity of p21 for PCNA drops 10 times. Moreover, if such flanking regions are replaced by
hydrophilic or negatively charged sequences, affinity is reduced by four orders of magnitude [29].
In conclusion, the whole C terminus of p21, from aa 139 to 164, generates a very strong binding site for
p21. It is, therefore, not surprising that p21 binds to the IDCL with much higher affinity than any other
known PCNA-interacting protein [30]. Experiments performed in vitro demonstrated that, indeed,
p21 is potentially capable of preventing PCNA interaction with replication factors, including DNA
polymerase δ, which is in charge of the elongation of the lagging strand [31]. A scheme of the PCNA
binding site within the p21 polypeptide is shown in Figure 1. However, it is not yet clear whether
p21 levels in cells are sufficient to displace replicative DNA polymerases from active replisomes. It is
also difficult to speculate on the consequence of such displacement. While initial parallelism with its
effect on CDK activity may suggest that the PCNA-mediated shut-down of DNA replication could
be advantageous for cells experiencing DNA damage, at second glance, such a conclusion might be
flawed. While CDK inhibition prevents the initiation of DNA replication [32], the interaction of p21
with PCNA at replisomes would block the cell cycle after the initialization of the S phase. In such
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a scenario, strong reduction in the speed of nascent DNA elongation or its total inhibition would
exacerbate the replication stress, a scenario that is not advantageous for the DDR [33,34]. Hence,
the role of p21–PCNA interaction in the S phase must not necessarily parallel the model described
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PCNA is a highly abundant protein, especially in cancer cells [35,36] Therefore, it is not clear
whether p21 levels that can titrate CDKs outside the S phase would ever be sufficient to titrate
PCNA within the S phase. While the p21/PCNA ratio was reported to never exceed a 1:1 ratio in
cells [37,38], a ratio f at least 10:1 is required to block DNA repair by nucleotide ex ision repair
(NER) in vi ro [38– 1]. p21 was reported to bl ck replicative DNA synthesis in vi ro as wel , doing so
wh n reaching a 100:1 ratio [42–44]. When assessing the effe t f p21 on PCNA-dependent DNA
synthesis in cells, several reports showed a limited or null effect of p21–PCNA interaction on DNA
replication [38,45–51]. However, few studies suggested that p21–PCNA interaction in cells might
result in the CDK-independent arrest of the cell cycle outside the S phase [52,53]. The mechanism by
which p21–PCNA interaction in the S phase ends up triggering arrest outside the S phase has not been
elucidated. The effect of p21 on NER in vivo is not conclusive either. Some reports indicate a null effect
of p21 on NER [54–58], while others reported that p21 overexpression causes NER inhibition [41,59].
Such differences may depe d on the levels of overexpression and the constructs used. One report
attemp ed to limit p21 overexpression levels to e amounts observed after endogenous p21 induction
with daunorubicin and actinomycin D. Under such verexpression conditions, cell-cycle arrest was
efficiently triggered by p21. However, this effect was fully lost when the CDK binding site (W49 to
R, F51 to S, and D52 to A) was disrupted. In contrast, PCNA binding to p21 did not affect cell-cycle
distribution, bulk DNA synthesis in the S phase, or even the NER-mediated DNA repair. [51]. Hence,
levels of p21 overexpression that equal the maximal levels reached by endogenous p21 may not suffice
to inhibit PCNA-mediated DNA synthesis by replicative DNA polymerases. As p21 levels during S
phase are much lower than the p21 levels induced by daunorubicin and actinomycin D, inhibition of
replicative DNA synthesis by endogenous p21 is highly unlikely. Moreover, as is discussed in the next
section, the low levels of p21 in the S phase cannot be raised in any known scenario, as p21 proteolysis
of p21 is highly upregulated in the S phase.
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3. p21 Levels are Differentially Regulated during and by Cell Cycle
It is an acknowledged fact within the research community that the accumulation of p21 triggers
cell-cycle arrest outside the S phase. In this section, however, we focus on a not-so-familiar yet
remarkable fact about p21. In the S phase, p21 is never upregulated, even when treating cells with
DNA-damaging agents that cause p21 accumulation to an extent that is easily detectable through a
Western blot. It is well known that p21 levels in cells are controlled by different mechanisms that include
but are not exclusively restricted to the activity of the following E3 ligases: SCFSkp2, CRL4Cdt2, MDM2/X
(or HDM2 in humans), CRL2LRR1, and APC/CCdc20. For details on such degradation mechanisms,
please refer to [51,60]. Moreover, de-ubiquitination also plays a role in the control of p21 levels in
living cells [61]. p21 levels increase steeply after challenging cells with DNA-damaging agents, mainly
because of the p53-triggered increase in p21 mRNA. Consequentially, Western blot analysis of whole-cell
extracts showed increased p21 protein levels after γ irradiation, daunorubicin, and actinomycin D
treatment. It is simplistic, however, to assume that p21 is equally induced in all phases of the cell cycle,
especially when taking into consideration that the activity of the above-mentioned ligases is controlled
in a cell-cycle-dependent manner. The activity of SCFSkp2, HDM2, and CRL4Cdt2 peaks at the beginning
of and during the S phase, and could counteract the p53-mediated accumulation of p21 [62–64]. It has
long been known that, in cells that are not challenged by exogenous damage (unperturbed cell cycle),
p21 levels in the S phase remain at their lowest [11]. Moreover, p21 degradation follows a strict timing,
and the acceleration of p21 degradation causes stalled replication forks in mid-S phase and sensitivity
to replication arrest [65]. Live-cell imaging recently confirmed that p21-GFP levels are the lowest and
even undetectable in the S phase [16]. Strikingly, this S-phase-specific low p21 level remains after γ
irradiation. Single-cell-based analysis and centrifugal-elutriation approaches showed that, while γ
irradiation causes p53 upregulation in all phases of the cell cycle, p21 is upregulated outside the S
phase, but not in cells transiting the S phase [63]. In that report, it was shown that the E3 ligase
involved in p21 degradation was Hdm-2, at least in some cell lines used in the study [63]. SCFSkp2
did not contribute to such γ-irradiation-associated p21 proteolysis in the S phase [63]. Since SCFSkp2
degrades cyclin–CDK-bound p21 [1], it is possible that the main signal forcing p21 degradation in the
S phase is associated with an E3 ligase that is active beyond the G1/S boundary. More recent studies
confirmed the more marginal effect of SCFSkp2, while the contribution of CRL4Cdt2 to p21 degradation
was central and required to promote both irreversible S-phase entry and to prevent premature S-phase
exit upon DNA damage [16]. After γ irradiation, the CRLCdt2-dependent degradation of p21 was
triggered by ATM (ataxia telangiectasia mutatated) activation [66].
Would p21–PCNA interaction then be needed for S-phase onset and shut-down? A recent
report that monitored single cells for 20 hours, combining noninvasive live-cell imaging of
CRISPR/Cas9-endogenous fluorescent p53 and p21 reporters and computational-based analysis
of multiple single-cell events, addressed such questions [67]. In agreement with [63], they showed
that γ-irradiation induced very reproducible kinetics of p53 induction in all cells, peaking at 4 hours
after treatment. In contrast, p21 accumulation was heterogeneous and in part uncoupled from p53
dynamics. In cells that were in Phases G1 and G2 at the time of irradiation, an immediate p21 response
followed p53 induction. Cells that were transiting the S phase at the time of irradiation induced a
delayed p21 response whose onset occurred when they reached the S-to-G2 transition [67]. Similar
results were reported when using other p53-inducing agents, radiomimetic drug neocarzinostatin
(NCS) and nutlin-3 [16,68]. While the mechanisms of p53 induction by nutlin-3 and γ irradiation are
dissimilar (nutlin-3 disrupts p53/MDM2 interaction [69], while γ irradiation attenuates such interaction
via the phosphorylation of MDM-2 and p53 [70]), both treatments converge into the accumulation of a
transcriptionally active p53 that can promote p21 accumulation. Moreover, under this circumstance,
live-cell imaging revealed that p21 accumulated in G1 was downregulated in the S phase, and then
accumulated rapidly again at the S/G2 transition [16]. Such modulation in p21 levels was intimately
associated with the interaction of p21 with PCNA, as disruption of such interaction through a mutation
of the p21 PIP box caused the accumulation of p21 in γ-irradiated cells transiting the S phase [67].
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Both studies concluded that the downregulation of p21 in the S phase was dependent on the CRL4cdt2
ligase, which degrades PCNA-bound p21 in the S phase [28]. In contrast, SCFSkp2 and Mdm2,
the other two ligases that mediate p21 degradation during the late G1 and early S phases, contributed
only marginally to the prevention of p21 accumulation in the S phase of γ-irradiated cells [16,67].
Intriguingly, the expression of a p21 mutant with a disrupted PCNA-binding domain (Q144A, M147A,
and F150A [71]) caused arrest in G1 after γ-irradiation [67], suggesting that p21–PCNA interaction
prevented rather than promoted cell-cycle arrest, as originally postulated based on its ability to displace
replicative DNA polymerases from PCNA [43,44]. Moreover, p21–PCNA interaction is needed to
prevent chromosome fusions and micronuclei that accumulate in cells expressing the p21 mutant
deficient in PCNA binding [67]. We speculate that such observation may suggest that, although p21
proteolysis is induced by γ-irradiation in the S phase, the interaction of endogenous p21 and PCNA
may favor genomic stability before CRL4cdt2-mediated proteolysis. Alternatively, liberating p21 from
PCNA interaction may cause dysregulated interaction between p21 and CDKs that favors genomic
instability with an unknown mechanism. In this regard, it should be mentioned that, in a manner that
depends on CDK inactivation, p21 was reported to regulate the homologous recombination-mediated
repair of double-strand-breaks (DSBs), a DNA lesion that is induced by γ irradiation [72]. A model
depicting the main conclusions of this section is shown in Figure 2.
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than p21 levels in Phase G2 [16]. Whether p21 controls PCNA functions in G1 is still debated, but p21 
overexpression levels, which are similar to highest levels reached by endogenous p21 after DNA 
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inducers of p21 [16,67,68]. These results indicate that excess of exogenous p21 is strongly prevented 
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Figure 2. Cell cycle imposes strong regulation on levels in S phase. Levels of fluoresc nce-tagged
p21, PCNA, and CDK activities presented by black, purple, and orange lines, respectively. Endogenous
p21 levels not shown, as live image experiments focused on fluorescence-tagged p21. Only in G1 and
G2 did p21 levels rise to an extent that could inhibit cyclin–kinase complexes such as CycE/CDK2.
Since p21 lev l i G1 ar very heterogeneous, multiple b ck lines repr ent such dispersion in p21
expression. Length of the G1 phase correlates with p21 levels, which were higher than p21 levels in Phase
G2 [16]. Whether p21 controls PCNA functions in G1 is still debated, but p21 overexpression levels,
which are similar to highest levels reached by endogenous p21 after DNA damage, are not sufficient
to modulate replicative DNA sy thesis or nucleotide excision repair in G1 [51]. In S phase, levels of
fluorescence-tagged p21 were undetectable both in unperturbed conditions and after γ-irradiation,
nutlin-3, or neocarzinostatin (NCS) treatment, which are all well-characterized inducers of p21 [16,67,68].
These results indicate that excess of exogenous p21 is strongly prevented in the S phase. Either Cdt2
downregulation or the disruption of the PIP box of p21 allowed p21 upregulation in the S phase,
indicating CRL4Cdt2 that degrades PCNA-bound p21, tightly controlling p21 levels in the S phase [16,67].
p21 represented as black linear and unstructured peptide; dotted p21 represent p21 degradation.
4. p21 Exerts Specific Functions at S-Phase-Specific Level, Regulating Genomic Stability through
PCNA Interaction
In the previous section, we discussed different reports demonstrating that, regardless of
p53-dependent p21 mRNA induction, p21 levels in the S phase are strongly downregulated. Moreover,
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γ-irradiation cannot trigger p21 accumulation in cells arrested in the S phase using ribonucleotide
reductase inhibition by hydroxyurea [73]. Such observations indicate that such a limitation of p21
levels in the S phase could never allow p21-dependent block replicative DNA polymerases. However,
recent reports that are discussed below indicated that subtle alterations in the levels of p21 in the S
phase affect the replication rate, perhaps by regulating the interaction of PCNA with other partners.
Such alterations in replication rate are followed by an increase in the frequency of genome-destabilizing
events, unmasking a crucial function of p21–PCNA interaction during the DDR activation in the
S phase.
(a) p21 levels influence the turnover of licensed replication origins. By exploring markers of active
replication (KI67) and p21 levels in human tumors, unexpected colocalization of p21 and ki67 was
observed in approximately 5% to 7% of cells within p53-deficient tumors [71]. Since such results indicated
that the S phase of p53-deficient cells could tolerate high p21 levels, cellular models that recapitulated
the results were generated. SAOS-2 cancer cells and Li-Fraumeni-derived fibroblasts were engineered
to express inducible p21 to levels that were similar to those induced by daunorubicin in p53-proficient
MCF-7 cells [71]. After the initial loss of proliferation capacity, a fraction of p21-overexpressing
cells evaded arrest/senescence, displaying upregulation of CDT1, CDC6, and ORC, which are all
regulators of replication origin licensing [74]. Because p21 has the strongest PCNA-binding affinity,
such a result suggested that excess p21 may cause CLR4Cdt2 ligase saturation. The dependency on
PCNA was confirmed using a p21 mutant with a disrupted PIP box (Q144A, M147A, and F150A),
which did not cause CDT1 and CDC6 upregulation [71]. p21-overexpressing cells acquired the
capacity to rereplicate. Moreover, replication-fork progression was asymmetric and slow, and DSBs
accumulated in a manner that depended on CDT1 and CDC6 overexpression. Because p21 overexpression
caused the downregulation of RAD51 [71], DSBs were processed by error-prone pathways, including
RAD52-dependent break-induced replication (BIR) and single-strand annealing (SSA) [75], and possibly
nonhomologous end-joining [71]. Because both rereplication and error-prone DSB repair fuel genomic
instability, these observations indicate a pro-oncogenic role of p21, at least in p53-negative cancer [71,75].
Reinforcing the link between p21 excess in S phase and the instability of the genome, in Caenorhabditis
elegans, p21 accumulation triggered by CRL4Cdt2 and SCFSkp2 inactivation causes nuclear retention of
CDC6 and rereplication [76]. We conclude that these reports demonstrate that, by competing with other
PCNA partners, p21 modulates PCNA-dependent functions in the S phase.
(b) p21 levels influence replication-fork speed. Endogenous p21 levels in unperturbed
p53-expressing cells are lower than in the scenario discussed in (a). Such p21 is considered residual
as it does not modulate unperturbed cell-cycle progression [77,78]. However, we showed that such
low p21 levels interact with PCNA at DNA replication factories [79]. When downregulating p21,
both in primary and tumor cells, nascent DNA elongation is impaired, hence suggesting that p21
is a positive regulator of undamaged-nascent DNA elongation [79]. Such a role of p21 requires an
intact PIP box, prevents the accumulation of replication stress markers, and protects genomic stability.
p21 downregulation causes the augmentation of common fragile-site instability and the accumulation
of micronuclei in a manner that depends on the loss of p21–PCNA interaction [79]. All defects observed
when p21 is downregulated were phenocopied in HCT116 cells in which p21 was stably knocked
out [14,79]. Mechanistically, such a role of p21 depends on its ability to displace PCNA partners from
the replisome. In this case, the PCNA partner that triggers the above-mentioned defects was the
dysregulated loading of specialized DNA polymerase κ to chromatin-bound PCNA [79]. Specialized
DNA polymerases are normally recruited to the replisome at replication barriers that stall ongoing forks.
In that context, specialized DNA polymerases promote DNA replication across barriers during a process
called translesion DNA synthesis. Such a canonical role of specialized DNA polymerases was reviewed
elsewhere [77,80]. However, in this case, the dysregulated loading of pol κ takes place on undamaged
DNA, hence causing its participation on undamaged DNA replication, not on TLS events. We postulate
that the replication speed on undamaged DNA is negatively affected when pol κ is in charge of DNA
synthesis, as pol κ is less processive than replicative DNA polymerases δ and ε. Remarkably, similar
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conclusions were reached when exploring DNA replication and genomic-instability parameters in the
context of the downregulation of the de-ubiquitinase of PCNA, ubiquitin-specific protease 1 (USP1) [81].
While replicative DNA polymerases dock on PCNA at its IDCL, specialized DNA polymerases such
as pol κ do so by binding both the IDCL and the ubiquitin moiety of PCNA [82]. Hence when
upregulating PCNA ubiquitination or downregulating competitors for IDCL binging, the choice of
DNA polymerases in charge of the replication of undamaged DNA is altered. Intriguingly, a more
recently published report indicated that p21 downregulation does not reduce, but instead increases
DNA elongation in ongoing forks [83]. Both reports [79,83] used the same cell line, but different siRNAs.
Another difference between those findings is that Mansilla et al. indicated no significant increase in
replication-fork asymmetry [79], while Maya Mendoza et al. found a certain level of asymmetry [83],
suggesting that DNA lesions accumulated in the second experiment settings. No p21 null models were
used in [83]. The biochemical mechanism that triggers the upregulation of replication speed in the
absence of p21 is yet unknown. Importantly, however, both reports [79,83] revealed that endogenous
p21 levels that were considered to be residual can control nascent DNA elongation, being capable of
enhancing or reducing replication speed. Intriguingly, endogenous p21 expression in the S phase was
recently reported to protect cancer cells from excessive DNA damage in the S phase, and cell killing
by Wee1 (MK1775) and Chk1 (AZD6772) kinase inhibitors [84,85]. Such a role of p21 is independent
of CDK inactivation, and may also depend on the modulation of PCNA interactions during the S
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recruitment of replicative DNA polymerase δ to DNA [51]. Such a result is intriguing because pol δ 
is also loaded to PCNA through PIP box domains [87]. However, replicative DNA polymerases are 
multimeric complexes containing PIP boxes in each subunit [87]. Given that PCNA is a trimer, the 
multiple docking options of replicative DNA polymerases may favor their recruitment to the 
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(top) While p53-proficie t cells do not allow p21 upregulation in the S phase, p53-deficient cells
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Increased p21 levels in the S hase saturate the CRL4Cdt2 E3 ligase, causing a upregulation of other
CRL4Cdt2 targets involved in origin firing [71]. Alterations in replication choreography are followed by
rereplication events and double-strand-break (DSB) accumul tion that are channeled into error-prone
repair, further fueling cell genomic instability [71,75].
Genes 2020, 11, 593 8 of 17
5. Genotoxins Do Not Induce p21 Accumulation in S Phase
The S-phase-specific impairment of p21 upregulation after γ-irradiation, NCS, and nutlin-3
was discussed in previous sections. We also debated evidence indicating that such low p21 levels
accumulated in unperturbed or γ-irradiated S phase cells are insufficient to attempt CDK inhibition,
but enough to modulate the occupancy of PCNA trimmers at replisomes. p21 is capable of modulating
the recruitment of many partners to the PCNA IDCL pocket without interfering with the recruitment
of replicative DNA polymerase δ to DNA [51]. Such a result is intriguing because pol δ is also loaded
to PCNA through PIP box domains [87]. However, replicative DNA polymerases are multimeric
complexes containing PIP boxes in each subunit [87]. Given that PCNA is a trimer, the multiple
docking options of replicative DNA polymerases may favor their recruitment to the replisome despite
endogenous p21 expression [88]. Consistently, we and others showed that pol δ recruitment to PCNA
is unaltered by changes in endogenous p21 expression [47,54,55,88].
Since the levels of p21 in an unperturbed S phase do not suffice to inhibit the DNA synthesis by
replicative DNA polymerases, they may not suffice after γ irradiation, NCS, or nutlin-3 treatments as
well [16,67,68]. Intriguingly, other genotoxins that do not cause cell-cycle arrest in the G1 and G2 phases
of the cell cycle, not only fail to induce p21 in the S phase, but happen to trigger p21 downregulation.
Agents such as hydroxyurea, aphidicolin, hypoxia and deferoxamine (DFX, hypoxia mimetic agents)
cause p21 downregulation both by negatively regulating its mRNA accumulation and by enhancing
its proteolysis [37,73,89–91]. Focusing on p21 protein degradation, several reports indicated that
proteasome-mediated p21 elimination is enhanced by UV irradiation in a dose- and time-dependent
manner [59,78,92–95]. Other genotoxic agents that can efficiently trigger p21 degradation are methyl
methanesulfonate (MMS) [94] and cisplatin [95]. All these agents cause replication-fork stalling
followed by ATR activation, a situation that may enhance further signaling events involved in p21
degradation [59,93]. Augmented p21 degradation after DNA damage by UV irradiation depends
mostly on CRL4Cdt2 and a noncanonical type of ubiquitination at its N-terminus [28,64,76,94,96,97].
Together, these observations highlight a counterintuitive concept: p21 is not upregulated in the S phase,
and its downregulation, not its accumulation, is required for optimal DDR after at least some types of
genotoxic stress.
6. CDK-Independent Effect of p21 Overexpression on Damaged DNA Replication, Cell Death,
and Genomic Stability
The results in the previous section indicated that p21–PCNA interaction may be actively prevented
after different types of genotoxic stress. A hint on the relevance of p21 downregulation in S-phase
post-UV irradiation came from the correlation between the timing of p21 degradation and the
recruitment of specialized DNA pol η to replication factories or chromatin-bound PCNA [51].
The recruitment of specialized pol η to DNA is particularly relevant for UV-triggered DNA-damaged
response. While replicative DNA polymerases cannot replicate through DNA lesions, such as those
caused by UV, specialized DNA polymerases incorporate nucleotides opposite damaged DNA [98].
In mammalian cells, such a role is achieved by pol η, pol ι, pol κ, and Rev 1 in the Y family, and pol ζ in
the B family of DNA polymerases. Such polymerases are poorly processive, have reduced fidelity due
to its lack of 3’–5’ proofreading activity, and possess active sites capable of accommodating damaged
or distorted templates [98]. The DNA damage-tolerance pathway that promotes the exchange between
replicative and specialized polymerases at stalled forks is known as translesion DNA synthesis (TLS).
The recruitment of specialized DNA polymerases to DNA is favored by the ubiquitination of PCNA,
thus providing a docking point for ubiquitin-binding domains in specialized DNA polymerases [24,99].
Despite the average poor fidelity of specialized polymerases, certain TLS events are not mutagenic when
using specific DNA lesions as replication templates. For example, pol η-mediated DNA synthesis across
the major UV photoproduct, cyclobutane pyrimidine dimers (CPDs), is poorly mutagenic [100,101].
The predisposition to skin cancer that characterizes xeroderma-pigmentosum-variant (XPV) disease,
lacking pol η expression, presumably results from a more mutagenic bypass of CPDs by other
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specialized polymerases [102,103]. Hence, p21 downregulation in the S phase may serve to permit the
correct onset of TLS events, perhaps even influencing the TLS–pol timing hierarchy [88]. The negative
role of p21 expression for the onset of TLS was demonstrated using a plasmid-based assay that
allows the quantification of the efficiency and mutagenicity of TLS events [104]. In such assays,
p21 reduces TLS capacity, but increases its accuracy, whereby this role depends on the ability of
p21 to bind PCNA [104]. Moreover, PCNA ubiquitination, a post-translational modification of
PCNA that promotes the recruitment of specialized polymerases to chromatin-bound PCNA, is also
affected by p21 levels. However, both the downregulation and overexpression of p21 were reported
to impair PCNA ubiquitination [94,104]. Such contrasting, at first sight, results may indicate a
bimodal effect of p21 on PCNA ubiquitination. A similar bimodal effect was previously reported
for the p21-mediated modulation of CDK4 activation [105]. The conclusion at that point was that
p21 downregulation after UV irradiation may favor TLS activation. If that were the case, then the
forced expression of p21 in the S phase should impair TLS, triggering a deficient DDR. To address
such a question, p21 stabilization was attempted. The construct used that resists UV-triggered p21
proteolysis contains a 6 myc-N-terminus tag that prevented ubiquitination at its N terminus [106].
A mutation on its CDK-binding domain allows unaltered cell-cycle progression in conditions of p21
overexpression [50,51]. Thus, in a manner that depends fully on PCNA binding, p21 overexpression
selectively blocked the recruitment of specialized DNA polymerases η, κ, and ι to replication factories
both before and after UV irradiation [50]. Rev1 recruitment to UV-damaged DNA is also fully blocked
by the expression of a stable p21 with an intact PIP box [50]. The interaction of specialized DNA
polymerases, importantly not the replicative Pol δ, with PCNA in chromatin immunoprecipitations
was also prevented by stable p21–PCNA interaction, and was released when the PIP box of p21
was mutated (M147 to A, D149 to A, and F150 to A-from [21]) [51]. The impairment of TLS also
affected nascent DNA elongation events, as revealed by the observation of single DNA molecules in
DNA spreading assays [50]. Importantly, TLS inhibition by stable p21–PCNA interaction correlates
with increased cell death and genomic instability after UV irradiation [50]. TLS inhibition after UV
irradiation can be achieved under experiment conditions, not only by p21 stabilization in the S phase.
PIP box domains with high PCNA affinity, such as the one of CDT1, also displace Pol η and Pol κ from
replication factories, causing cell death [107]. To achieve such an effect, the PIP box of CDT1 requires a
disrupting mutation of its degron (a substitution of the R-to-A amino acid in position +4 from the C
terminus of the PIP box), which guarantees its stabilization [107]. Such mutation types indeed prevent
the degradation of PIP box proteins with high affinity for PCNA [28]. Hence, PIP box domains with
high affinity for PCNA can prevent the binding of specialized DNA polymerases to the clamp loader.
Conversely, the expression of a chimeric specialized polymerase κwith increased affinity for PCNA
also causes a similarly unstable outcome [81]. Hence, a very dynamic equilibrium of p21 interactions is
required, ensuring conditions for replicative and specialized DNA polymerases to promote scheduled
nascent DNA elongation at replication forks. While on undamaged DNA, p21 displaces specialized
DNA polymerases favoring DNA replication by pol δ and pol ε, the encounter of a replication fork with
a DNA lesion must promote the rapid CRL4Cdt2-dependent proteolysis of p21 to allow the utilization
of damaged DNA as templates for DNA synthesis by specialized DNA polymerases [77]. A model
depicting the main conclusions of this section is shown in Figure 4.
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TLS inhibition may cause alterations in the DDR that do not favor tumor adaptation to 
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pol η in ovarian-cancer-cell models [110]. The upregulation of miR-93, a microRNA that triggers pol 
η degradation, also enhanced the effect of cisplatin [110]. The development of drugs interfering with 
different aspects of the TLS pathway was also attempted with promising results [113–116]. These 
compounds, however, cannot achieve complete TLS inhibition. One compound to highlight is T2AA, 
recently described to inhibit the interaction of specialized DNA polymerases with PCNA [117]. 
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p21–PCNA interaction [50,51]. Another strategy is to inhibit the mutagenic branch of TLS by 
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7. Therapeutic Op ortunities for Cancer re t
Because TLS events may protect tu ring DNA replication, TLS is consid red a
potential target in cancer t [98,108,109]. The protective r le of TLS i cancer is r vealed by
the ov rexpression of pol η in ovarian-cancer cells, which is videnced in populations that resist
cisplatin treatment [110]. Such an adaptive increase in pol η levels was also reported in fibroblasts
treated with UV light [111]. Supporting the relevance of TLS in cancer therapy, the elimination of
pol η during UV or cisplatin treatment causes acute replication stress in the S phase, leading to
the augmentation of a type of cell death that is not accompanied by micronuclei or chromosome
aberrations [112]. Hence, TLS inhibition may cause alterations in the DDR that do not favor tumor
adaptation to chemotherapeutic treatments. The effect of cisplatin was enhanced when simultaneously
depleting pol η in ovarian-cancer-cell models [110]. The upregulation of miR-93, a microRNA
that triggers pol η degradation, also enhanced the effect of cisplatin [110]. The development of
drugs interfering with different aspects of the TLS pathway was also attempted with promising
results [113–116]. These compounds, however, cannot achieve complete TLS inhibition. One compound
to highlight is T2AA, recently described to inhibit the interaction of specialized DNA polymerases
with PCNA [117]. Nevertheless, when used at higher concentrations, it can also inhibit replicative
polymerases [117]. Such a result demonstrates that TT2A does not have the specificity for the TLS
pathway reported for p21–PCNA interaction [50,51]. Another strategy is to inhibit the mutagenic branch
of TLS by disrupting pol ζ and Rev1 protein interactions [118,119]. Recently, a small molecule that
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disrupts this interaction and sensitizes tumors to cisplatin was developed, also demonstrating in vivo
efficacy [120]. One more potentially druggable target in the TLS pathway is PCNA ubiquitination [24,99].
Such a post-transcriptional modification of PCNA can also be inhibited by using AKT inhibitors.
Such impairment in PCNA ubiquitination enhances the killing of cancer cells treated with cisplatin,
displaying an even more potent effect in homologous recombination-deficient cells [121]. In addition,
drugs that target p21 may be of use. The inactivation of cullin E3 ligases with pevonedistat (MLN4924)
inhibits the proliferation of melanoma cell lines in vitro through the prevention of p21 degradation [122].
Lastly, nanoparticle-based preclinical studies in which TLS polymerases were targeted with siRNA in
combination with cisplatin [123] also indicated that TLS inhibition mediated by PIP box peptides or
novel drugs may pave avenues towards the improvement of cancer treatments.
8. Concluding Remarks
While the concept of p21 as a cyclin kinase inhibitor is massively accepted by the research
community, the possibility that such a renowned function of p21 exerts a “secondary” role is far
from being acknowledged. For multiple rounds of cell division, cells that cycle freely may not
accumulate enough p21 to inhibit CDKs. However, in every cell cycle, cells express p21 in the S
phase in such amounts that are enough to fulfill PCNA-mediated functions. Despite the average
Western blot showing a faint, almost undetectable p21 band, such an amount of p21 is enough to
regulate key aspects of DNA replication events in every cell cycle. This notion is supported by several
reports [16,67,75,79,83,86], which demonstrate that endogenous p21, and specifically the fraction
expressed in the S phase, has an important role in the control of unperturbed and damaged DNA
replication. Moreover, the upregulation of wild-type [75] and a mutant version of p21 [50,67] impairs
replicative DNA synthesis. Intriguingly, the downregulation of p21 also interferes with the optimal
processivity of DNA replication [79,83,86]. Hence, any perturbation in the p21 levels in the S phase may
have negative effects on DNA replication parameters, ultimately causing the activation of a deficient
DDR. As p21 is rarely genetically affected in cancers [1,124], the targeting of p21 may have positive
results in the clinic [84,85].
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